Medtronic’s valuation presents a compelling opportunity for value investors. The stock has traded significantly below its DCF value, suggesting a market mispricing. With a Forward P/E of 9.65 and an Earnings Yield of 4.82%, the company appears undervalued relative to its earnings potential. The Altman Z-score of 2.69 indicates moderate financial health, suggesting stability but not without risks. Overall, the market seems to have overlooked its growth prospects, creating a potential entry point for savvy investors.